Ekso Bionics Holdings, Inc.
NASDAQ:EKSO · NASDAQ Capital Market
+$2.84 today
Vol 0.13M · Avg 0.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:EKSO · Revenue to Net Income
Key Ratios
Analysis
$11.6M of revenue converted into -$15.7M of net income for the selected period. Gross margin is 50.9% and net margin is -158.9%, showing how much revenue survives after costs and taxes. EPS is $-5.39, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.8M -28.6% | $17.9M -1.9% | $18.3M +41.6% | $12.9M +14.8% | $11.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $6.0M -29.2% | $8.4M -8.5% | $9.2M +37.4% | $6.7M +48.9% | $4.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $6.8M -28.0% | $9.5M +4.8% | $9.1M +46.1% | $6.2M -7.9% | $6.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 53.5% +0.4pp | 53.1% +3.4pp | 49.7% +1.5pp | 48.1% -11.9pp | 60.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $3.0M -21.8% | $3.9M -22.9% | $5.0M +38.6% | $3.6M +32.0% | $2.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $17.1M +6.5% | $16.1M -16.0% | $19.2M +5.6% | $18.1M +1.8% | $17.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $20.2M +1.0% | $20.0M -17.4% | $24.2M +11.1% | $21.8M +5.8% | $20.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.6M -2.2% | $1.6M -5.3% | $1.7M +91.4% | $887.0K +58.1% | $561.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$9.8M -3.8% | -$9.5M +28.4% | -$13.2M +6.0% | -$14.0M -54.4% | -$9.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -76.7% -23.9pp | -52.7% +19.5pp | -72.2% +36.5pp | -108.7% -27.9pp | -80.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$13.3M -27.4% | -$10.5M +30.8% | -$15.1M +2.9% | -$15.6M -12.5% | -$13.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -104.1% -45.8pp | -58.4% +24.3pp | -82.7% +37.8pp | -120.5% +2.5pp | -123.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $309.0K +14.9% | $269.0K -10.9% | $302.0K +93.6% | $156.0K +38.1% | $113.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.6M +287.5% | -$870.0K -911.6% | -$86.0K -118.1% | $476.0K -88.3% | $4.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$11.7M -3.2% | -$11.3M +25.5% | -$15.2M -0.8% | -$15.1M -54.4% | -$9.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -91.4% -28.2pp | -63.2% +19.9pp | -83.1% +33.6pp | -116.8% -30.0pp | -86.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$11.7M -3.2% | -$11.3M +25.5% | -$15.2M -0.8% | -$15.1M -54.4% | -$9.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -91.4% -28.2pp | -63.2% +19.9pp | -83.1% +33.6pp | -116.8% -30.0pp | -86.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$5 +41.8% | -$8 +48.7% | -$16 +5.8% | -$17 -45.3% | -$12 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$5 +41.8% | -$8 +48.7% | -$16 +5.8% | -$17 -32.2% | -$13 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $2.4M +80.5% | $1.3M +45.4% | $924.5K +7.0% | $864.1K +6.3% | $812.9K | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $2.4M +80.5% | $1.3M +45.4% | $924.5K +7.0% | $864.1K +5.6% | $817.9K | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Adlai Nortye Ltd.
NASDAQ:ANL
$536.11M
Aytu BioPharma, Inc.
AYTU
$18.71M
OSR Holdings, Inc.
OSRH
$9.63M
Allurion Technologies Inc.
ALUR
$4.38M
Co-Diagnostics, Inc.
CODX
$3.76M
Ernexa Therapeutics Inc.
ERNA
$1.95M
Aethlon Medical, Inc.
AEMD
$1.44M
GeoVax Labs, Inc.
GOVX
$1.28M
ProPhase Labs, Inc.
PRPH
$355,276.00
enVVeno Medical Corporation
NVNO
$165,030.00
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EKSO generate?
Ekso Bionics Holdings, Inc. (EKSO) reported $12.80M of revenue in fiscal 2025.
Is EKSO profitable?
Ekso Bionics Holdings, Inc. (EKSO) reported -$11,695,000.00 of net income, with a net margin of -91.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.